Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Dr John Byrd - The Ohio State University, Columbus, USA
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )
31 May 2014

Upcoming trends in myeloma therapy

Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson
Upcoming trends in myeloma therapy ( Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson )
15 May 2014

Recent advances in mantle cell lymphoma: Expert panel discussion

Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele Zucci
Recent advances in mantle cell lymphoma: Expert panel discussion ( Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele Zucci )
13 May 2014

Lecture: Current use of systemic therapies in localised disease

Dr Rainy Umbas - University of Indonesia, Jakarta, Indonesia
Lecture: Current use of systemic therapies in localised disease ( Dr Rainy Umbas - University of Indonesia, Jakarta, Indonesia )
12 May 2014

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for)

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia
Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for) ( Dr Paul de Souza - University of Western Sydney, New South Wales, Australia )
12 May 2014

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (against)

Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany
Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (against) ( Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany )
12 May 2014

Rituximab versus idelalisib in refractory CLL

Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University Hospital, Leeds, UK
Rituximab versus idelalisib in refractory CLL ( Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University  Hospital, Leeds, UK )
9 May 2014

Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients

Dr Valentin Goede - University of Cologne, Cologne, Germany
Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients ( Dr Valentin Goede - University of Cologne, Cologne, Germany )
8 May 2014

WIN Symposium 2014: Breakthrough biomarker investigations and combination therapies

Dr John Mendelsohn, Dr Razelle Kurzrock, Dr Mace Rothenberg
WIN Symposium 2014: Breakthrough biomarker investigations and combination therapies ( Dr John Mendelsohn, Dr Razelle Kurzrock, Dr Mace Rothenberg )
6 May 2014

Work and history of the Kidney Cancer Association

Carrie Konosky - Vice President of Development & Public Affairs, Kidney Cancer Association, Chicago, USA
Work and history of the Kidney Cancer Association ( Carrie Konosky - Vice President of Development & Public Affairs, Kidney Cancer Association, Chicago, USA )
6 May 2014

Kidney cancer treatment ten years from now

Prof Martin Gore - The Royal Marsden Hospital, London, UK
Kidney cancer treatment ten years from now ( Prof Martin Gore - The Royal Marsden Hospital, London, UK )
6 May 2014

Personalisation of leukaemia treatment using genome sequencing

Dr Giovanni Martinelli - University of Bologna, Bologna, Italy
Personalisation of leukaemia treatment using genome sequencing ( Dr Giovanni Martinelli - University of Bologna, Bologna, Italy )
5 May 2014